Format

Send to

Choose Destination
Biomed Pharmacother. 2013 Jul;67(6):539-42. doi: 10.1016/j.biopha.2013.01.008. Epub 2013 Feb 18.

¹⁸F-FDG-PET/CT in malignant mesothelioma.

Author information

1
Nuclear Medicine Unit, Fondazione Salvatore Maugeri, Pavia, Italy. chiara.fuccio@gmail.com

Abstract

It is well known the useful role of ¹⁸F-FDG-PET/CT for differential diagnosis between benign and malignant disease, for staging, for monitoring response and for prognosis regarding mesothelioma. Recently, literature was enriched with new interesting studies regarding the potential applications of ¹⁸F-FDG-PET/CT in this field. The purpose of this review is to evaluate articles published on line (PubMed) from January 2011 until October 2012 in order to obtain an overview of recent progress of molecular imaging in malignant mesothelioma. The main topics concern the use of ¹⁸F-FDG-PET/CT in radiation therapy planning, monitoring of treatment (surgery/chemotherapy) response and prognosis assessment.

KEYWORDS:

(18)F-FDG-PET/CT; Malignant mesothelioma; Prognosis; Radiation therapy planning; Treatment response

PMID:
23583476
DOI:
10.1016/j.biopha.2013.01.008
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center